Back to Newsroom

Cystic Fibrosis Foundation Therapeutics Announces $5 Million Award to Support Development of Anti-Inflammatory Treatment

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.

The award will help fund a Phase 2 clinical trial of Resunab, a novel synthetic oral drug. Resunab has the potential to address inflammation in people with CF, regardless of an individual’s CF gene mutations.

In people who have cystic fibrosis, lung inflammation is a chronic and life-threatening result of the disease, causing scarring and progressive lung damage.

Click here to read more